Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma
Micro-Abstract The oncogenic driver epidermal growth factor receptor (EGFR) mutations upregulate immune checkpoint proteins programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) in in vitro and in vivo models of non–small-cell lung cancer (NSCLC). Immunohistochemistry revealed that PD-L1 and P...
Gespeichert in:
| Veröffentlicht in: | Clinical lung cancer 2015-09, Vol.16 (5), p.e25-e35 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e35 |
|---|---|
| container_issue | 5 |
| container_start_page | e25 |
| container_title | Clinical lung cancer |
| container_volume | 16 |
| creator | Lin, Cheng Chen, Xiong Li, Meifang Liu, Jingnan Qi, Xingfeng Yang, Wenting Zhang, Hairong Cai, Zhongfu Dai, Yun Ouyang, Xuenong |
| description | Micro-Abstract The oncogenic driver epidermal growth factor receptor (EGFR) mutations upregulate immune checkpoint proteins programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) in in vitro and in vivo models of non–small-cell lung cancer (NSCLC). Immunohistochemistry revealed that PD-L1 and PD-1 were positive in 53.6% and 32.1% of tumor specimens in a cohort of 56 patients with NSCLC carrying EGFR mutations, respectively. PD-L1 expression correlated with a better response to EGFR tyrosine kinase inhibitors and longer survival. |
| doi_str_mv | 10.1016/j.cllc.2015.02.002 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1706208677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1525730415000558</els_id><sourcerecordid>1706208677</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-3ca854cde55e003f533c4ebd68a21d4833751a7cad26ba3ad2f3c18e54782b5a3</originalsourceid><addsrcrecordid>eNp9ks9u1DAQxiMEoqXwAhyQj1wS_CdOXAkhtcu2VCxiBUUcLa892fWS2MF2CvuIvBWOtnDgwGlGo-_7pJnfFMVzgiuCSfNqX-m-1xXFhFeYVhjTB8UpOWeixM05fph7TnnZMlyfFE9i3GdBwwh9XJxQLjBpOT4tfq2D3wY1DGDQW1BpV67sVjmDCFr-HAPEaL1D6wDG6hTR7SH4aB2g99apCOjG7ezGJh_QJ4ijd3k0my8hJQhoznZZH5F1SKGF3_mQkO_QWiULLud9tWmHlqM1EAbVo-vgf-TBldLHSA3j3HyYUjZ4V65zWLJ3gFaT26ILA85rFbR1flBPi0ed6iM8u69nxZer5e3iXbn6eH2zuFiVuhYklUwrwWttgHPAmHWcMV3DxjRCUWJqwVjLiWq1MrTZKJZLxzQRwOtW0A1X7Kx4ecwdg_8-QUxysFFD3ysHfoqStLihWDRtm6X0KNX5ajFAJ8dgBxUOkmA5I5R7OSOUM0KJqcyEsunFff60yVT-Wv4wy4LXRwHkLe8sBBl1vqbOiALoJI23_89_849d99ZZrfpvcIC491Nw-X6SyJgN8vP8RPMPEY4x5lyw36lSxfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1706208677</pqid></control><display><type>article</type><title>Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Lin, Cheng ; Chen, Xiong ; Li, Meifang ; Liu, Jingnan ; Qi, Xingfeng ; Yang, Wenting ; Zhang, Hairong ; Cai, Zhongfu ; Dai, Yun ; Ouyang, Xuenong</creator><creatorcontrib>Lin, Cheng ; Chen, Xiong ; Li, Meifang ; Liu, Jingnan ; Qi, Xingfeng ; Yang, Wenting ; Zhang, Hairong ; Cai, Zhongfu ; Dai, Yun ; Ouyang, Xuenong</creatorcontrib><description>Micro-Abstract The oncogenic driver epidermal growth factor receptor (EGFR) mutations upregulate immune checkpoint proteins programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) in in vitro and in vivo models of non–small-cell lung cancer (NSCLC). Immunohistochemistry revealed that PD-L1 and PD-1 were positive in 53.6% and 32.1% of tumor specimens in a cohort of 56 patients with NSCLC carrying EGFR mutations, respectively. PD-L1 expression correlated with a better response to EGFR tyrosine kinase inhibitors and longer survival.</description><identifier>ISSN: 1525-7304</identifier><identifier>EISSN: 1938-0690</identifier><identifier>DOI: 10.1016/j.cllc.2015.02.002</identifier><identifier>PMID: 25801750</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Adenocarcinoma of Lung ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; B7-H1 Antigen - genetics ; Biomarkers, Tumor - metabolism ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; Disease-Free Survival ; EGFR mutation ; EGFR-TKI therapy ; ErbB Receptors - antagonists & inhibitors ; ErbB Receptors - genetics ; Female ; Follow-Up Studies ; Gene Expression Regulation, Neoplastic ; Hematology, Oncology and Palliative Medicine ; Humans ; Immunohistochemistry ; Lung adenocarcinoma ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Male ; Middle Aged ; Mutation ; PD-L1 ; Prognosis ; Protein Kinase Inhibitors - pharmacology ; Protein Kinase Inhibitors - therapeutic use ; Pulmonary/Respiratory ; Survival Rate</subject><ispartof>Clinical lung cancer, 2015-09, Vol.16 (5), p.e25-e35</ispartof><rights>Elsevier Inc.</rights><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-3ca854cde55e003f533c4ebd68a21d4833751a7cad26ba3ad2f3c18e54782b5a3</citedby><cites>FETCH-LOGICAL-c481t-3ca854cde55e003f533c4ebd68a21d4833751a7cad26ba3ad2f3c18e54782b5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.cllc.2015.02.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25801750$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Cheng</creatorcontrib><creatorcontrib>Chen, Xiong</creatorcontrib><creatorcontrib>Li, Meifang</creatorcontrib><creatorcontrib>Liu, Jingnan</creatorcontrib><creatorcontrib>Qi, Xingfeng</creatorcontrib><creatorcontrib>Yang, Wenting</creatorcontrib><creatorcontrib>Zhang, Hairong</creatorcontrib><creatorcontrib>Cai, Zhongfu</creatorcontrib><creatorcontrib>Dai, Yun</creatorcontrib><creatorcontrib>Ouyang, Xuenong</creatorcontrib><title>Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma</title><title>Clinical lung cancer</title><addtitle>Clin Lung Cancer</addtitle><description>Micro-Abstract The oncogenic driver epidermal growth factor receptor (EGFR) mutations upregulate immune checkpoint proteins programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) in in vitro and in vivo models of non–small-cell lung cancer (NSCLC). Immunohistochemistry revealed that PD-L1 and PD-1 were positive in 53.6% and 32.1% of tumor specimens in a cohort of 56 patients with NSCLC carrying EGFR mutations, respectively. PD-L1 expression correlated with a better response to EGFR tyrosine kinase inhibitors and longer survival.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Adenocarcinoma of Lung</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>B7-H1 Antigen - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Disease-Free Survival</subject><subject>EGFR mutation</subject><subject>EGFR-TKI therapy</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>ErbB Receptors - genetics</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lung adenocarcinoma</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>PD-L1</subject><subject>Prognosis</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pulmonary/Respiratory</subject><subject>Survival Rate</subject><issn>1525-7304</issn><issn>1938-0690</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks9u1DAQxiMEoqXwAhyQj1wS_CdOXAkhtcu2VCxiBUUcLa892fWS2MF2CvuIvBWOtnDgwGlGo-_7pJnfFMVzgiuCSfNqX-m-1xXFhFeYVhjTB8UpOWeixM05fph7TnnZMlyfFE9i3GdBwwh9XJxQLjBpOT4tfq2D3wY1DGDQW1BpV67sVjmDCFr-HAPEaL1D6wDG6hTR7SH4aB2g99apCOjG7ezGJh_QJ4ijd3k0my8hJQhoznZZH5F1SKGF3_mQkO_QWiULLud9tWmHlqM1EAbVo-vgf-TBldLHSA3j3HyYUjZ4V65zWLJ3gFaT26ILA85rFbR1flBPi0ed6iM8u69nxZer5e3iXbn6eH2zuFiVuhYklUwrwWttgHPAmHWcMV3DxjRCUWJqwVjLiWq1MrTZKJZLxzQRwOtW0A1X7Kx4ecwdg_8-QUxysFFD3ysHfoqStLihWDRtm6X0KNX5ajFAJ8dgBxUOkmA5I5R7OSOUM0KJqcyEsunFff60yVT-Wv4wy4LXRwHkLe8sBBl1vqbOiALoJI23_89_849d99ZZrfpvcIC491Nw-X6SyJgN8vP8RPMPEY4x5lyw36lSxfw</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Lin, Cheng</creator><creator>Chen, Xiong</creator><creator>Li, Meifang</creator><creator>Liu, Jingnan</creator><creator>Qi, Xingfeng</creator><creator>Yang, Wenting</creator><creator>Zhang, Hairong</creator><creator>Cai, Zhongfu</creator><creator>Dai, Yun</creator><creator>Ouyang, Xuenong</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150901</creationdate><title>Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma</title><author>Lin, Cheng ; Chen, Xiong ; Li, Meifang ; Liu, Jingnan ; Qi, Xingfeng ; Yang, Wenting ; Zhang, Hairong ; Cai, Zhongfu ; Dai, Yun ; Ouyang, Xuenong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-3ca854cde55e003f533c4ebd68a21d4833751a7cad26ba3ad2f3c18e54782b5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Adenocarcinoma of Lung</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>B7-H1 Antigen - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Disease-Free Survival</topic><topic>EGFR mutation</topic><topic>EGFR-TKI therapy</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>ErbB Receptors - genetics</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lung adenocarcinoma</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>PD-L1</topic><topic>Prognosis</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pulmonary/Respiratory</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Cheng</creatorcontrib><creatorcontrib>Chen, Xiong</creatorcontrib><creatorcontrib>Li, Meifang</creatorcontrib><creatorcontrib>Liu, Jingnan</creatorcontrib><creatorcontrib>Qi, Xingfeng</creatorcontrib><creatorcontrib>Yang, Wenting</creatorcontrib><creatorcontrib>Zhang, Hairong</creatorcontrib><creatorcontrib>Cai, Zhongfu</creatorcontrib><creatorcontrib>Dai, Yun</creatorcontrib><creatorcontrib>Ouyang, Xuenong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical lung cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Cheng</au><au>Chen, Xiong</au><au>Li, Meifang</au><au>Liu, Jingnan</au><au>Qi, Xingfeng</au><au>Yang, Wenting</au><au>Zhang, Hairong</au><au>Cai, Zhongfu</au><au>Dai, Yun</au><au>Ouyang, Xuenong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma</atitle><jtitle>Clinical lung cancer</jtitle><addtitle>Clin Lung Cancer</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>16</volume><issue>5</issue><spage>e25</spage><epage>e35</epage><pages>e25-e35</pages><issn>1525-7304</issn><eissn>1938-0690</eissn><abstract>Micro-Abstract The oncogenic driver epidermal growth factor receptor (EGFR) mutations upregulate immune checkpoint proteins programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) in in vitro and in vivo models of non–small-cell lung cancer (NSCLC). Immunohistochemistry revealed that PD-L1 and PD-1 were positive in 53.6% and 32.1% of tumor specimens in a cohort of 56 patients with NSCLC carrying EGFR mutations, respectively. PD-L1 expression correlated with a better response to EGFR tyrosine kinase inhibitors and longer survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25801750</pmid><doi>10.1016/j.cllc.2015.02.002</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1525-7304 |
| ispartof | Clinical lung cancer, 2015-09, Vol.16 (5), p.e25-e35 |
| issn | 1525-7304 1938-0690 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1706208677 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adenocarcinoma - drug therapy Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma of Lung Adult Aged Aged, 80 and over Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use B7-H1 Antigen - genetics Biomarkers, Tumor - metabolism Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Disease-Free Survival EGFR mutation EGFR-TKI therapy ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Female Follow-Up Studies Gene Expression Regulation, Neoplastic Hematology, Oncology and Palliative Medicine Humans Immunohistochemistry Lung adenocarcinoma Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Male Middle Aged Mutation PD-L1 Prognosis Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pulmonary/Respiratory Survival Rate |
| title | Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T11%3A51%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Programmed%20Death-Ligand%201%20Expression%20Predicts%20Tyrosine%20Kinase%20Inhibitor%20Response%20and%20Better%20Prognosis%20in%20a%20Cohort%20of%20Patients%20With%20Epidermal%20Growth%20Factor%20Receptor%20Mutation-Positive%20Lung%20Adenocarcinoma&rft.jtitle=Clinical%20lung%20cancer&rft.au=Lin,%20Cheng&rft.date=2015-09-01&rft.volume=16&rft.issue=5&rft.spage=e25&rft.epage=e35&rft.pages=e25-e35&rft.issn=1525-7304&rft.eissn=1938-0690&rft_id=info:doi/10.1016/j.cllc.2015.02.002&rft_dat=%3Cproquest_cross%3E1706208677%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1706208677&rft_id=info:pmid/25801750&rft_els_id=1_s2_0_S1525730415000558&rfr_iscdi=true |